You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Aggressive lymphoma

Showing 26 - 50 of 6,546
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Hodgkin Lymphoma Trial in Cologne, Essen (CTL019)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Cologne, Germany
  • +1 more
Mar 2, 2022

Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)

Completed
Has Results
  • Non-Hodgkin's Lymphoma
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Non Hodgkin Lymphoma Trial (Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level

Not yet recruiting
  • Non Hodgkin Lymphoma
  • Liposomal Mitoxantrone Hydrochloride dose level 1
  • +6 more
  • (no location specified)
Mar 17, 2022

Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma Trial in Chicago, Boston, Omaha (Pembrolizumab)

Suspended
  • Lymphoma
  • +3 more
  • Chicago, Illinois
  • +3 more
Jan 30, 2023

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Spokane, Washington
  • +1 more
Aug 12, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Austria, Germany (Glofitamab, Rituximab, Obinutuzumab)

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Linz, Austria
  • +17 more
Mar 22, 2023

NHL, DLBCL, Non-hodgkin's Lymphoma Trial in United Kingdom, United States (AZD9150, Acalabrutinib, AZD6738)

Completed
  • NHL
  • +3 more
  • Los Angeles, California
  • +11 more
Aug 11, 2022

Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt

Active, not recruiting
  • Prolymphocytic Leukemia
  • +4 more
  • Columbus, Ohio
  • +1 more
Apr 29, 2022

DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)

Completed
  • Diffuse Large B-Cell Lymphoma
  • High Grade B-Cell Lymphoma
  • Boston, Massachusetts
  • +5 more
Aug 23, 2022

Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +13 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 18, 2022

Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma Trial in Australia, United States (NKX019)

Recruiting
  • Lymphoma, Non-Hodgkin
  • +9 more
  • NKX019
  • Denver, Colorado
  • +6 more
Jan 19, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma Trial in China (Rituximab, Etoposide,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Changsha, Hunan, China
  • +5 more
Jan 24, 2022

DLBCL - Diffuse Large B Cell Lymphoma Trial in Italy

Recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
    • Bologna, Italy
    • +12 more
    Sep 4, 2023

    High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,

    Recruiting
    • High Grade B-Cell Lymphoma, Not Otherwise Specified
    • +4 more
    • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
    • R-CHOP; R-DA-EPOCH; R-HD MTX
    • Jinan, Shandong, China
      Department of Hematology, Shandong Provincial Hospital
    Dec 7, 2021

    Lymphoma, B-Cell Trial in Vancouver, Toronto, Montreal (Venetoclax, RiTUXimab Injection, Rituximab SC)

    Recruiting
    • Lymphoma, B-Cell
    • Vancouver, British Columbia, Canada
    • +2 more
    Jan 24, 2022

    Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

    Suspended
    • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
    • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jul 6, 2022

    B-cell Lymphoma, Burkitt Lymphoma Trial in Milwaukee (Etoposide, Doxorubicin, Cyclophosphamide)

    Not yet recruiting
    • B-cell Lymphoma
    • Burkitt Lymphoma
    • Milwaukee, Wisconsin
      Froedtert Hospital & the Medical College of Wisconsin
    Jun 11, 2022

    Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) Trial in

    Active, not recruiting
    • Follicular Lymphoma Patients (Phase IB)
    • Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
    • Lenalidomide and GA101
    • Antwerpen, Belgium
    • +24 more
    Apr 6, 2022

    High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified,

    Recruiting
    • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
    • +4 more
    • Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
    • Jinan, Shandong, China
      Shandong Provincial Hospital
    Nov 18, 2021

    R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

    Recruiting
    • R/R CD19-Positive B-Cell Malignancies
    • +2 more
    • CNTY-101
    • +2 more
    • Detroit, Michigan
    • +1 more
    Dec 21, 2022

    T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

    Recruiting
    • T-cell Lymphoma
    • +30 more
    • Optional Blood Sample
    • Optional Nail Sample
    • Duarte, California
    • +25 more
    Jul 28, 2023

    Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,

    Active, not recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +9 more
    • Cryosurgery
    • +5 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Aug 9, 2022

    Non-Hodgkin Lymphoma Trial in Worldwide (Mosunetuzumab, Polatuzumab vedotin, Tocilizumab)

    Recruiting
    • Non-Hodgkin Lymphoma
    • Buenos Aires, Argentina
    • +18 more
    Aug 10, 2022

    Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)

    Completed
    Has Results
    • Lymphoma, T-Cell
    • Lymphoma, Extranodal NK-T-Cell
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Feb 3, 2022